Dx Deal Review Q3 2023

With recent approvals of expensive personalised and targeted therapies the pressure to make these available to patients where the impact will be most effective is increasing. Diagnostics have a key role to play and this quarter we notice an increase in diagnostics deals in the CNS disease area where there is huge unmet medical need.